PuraPharm Corporation Limited (1498.HK)
HKD 0.47
(-2.08%)
HKD 0.47
(-2.08%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 843.96 Million HKD | -16.97% |
| 2022 | 1.01 Billion HKD | -15.7% |
| 2021 | 1.2 Billion HKD | -12.27% |
| 2020 | 1.37 Billion HKD | 12.46% |
| 2019 | 1.22 Billion HKD | -8.32% |
| 2018 | 1.33 Billion HKD | 3.02% |
| 2017 | 1.29 Billion HKD | 50.42% |
| 2016 | 860.24 Million HKD | 23.36% |
| 2015 | 697.33 Million HKD | 65.91% |
| 2014 | 420.31 Million HKD | 20.74% |
| 2013 | 348.11 Million HKD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 781.73 Million HKD | -7.37% |
| 2023 Q2 | 946.38 Million HKD | -6.9% |
| 2023 FY | 843.96 Million HKD | -16.97% |
| 2023 Q4 | 843.96 Million HKD | -10.82% |
| 2022 FY | 1.01 Billion HKD | -15.7% |
| 2022 Q4 | 1.01 Billion HKD | -6.03% |
| 2022 Q2 | 1.08 Billion HKD | -10.29% |
| 2021 FY | 1.2 Billion HKD | -12.27% |
| 2021 Q4 | 1.2 Billion HKD | -11.4% |
| 2021 Q2 | 1.36 Billion HKD | -0.99% |
| 2020 Q4 | 1.37 Billion HKD | 12.02% |
| 2020 Q2 | 1.22 Billion HKD | 0.39% |
| 2020 FY | 1.37 Billion HKD | 12.46% |
| 2019 FY | 1.22 Billion HKD | -8.32% |
| 2019 Q4 | 1.22 Billion HKD | -8.86% |
| 2019 Q2 | 1.34 Billion HKD | 0.59% |
| 2018 Q4 | 1.33 Billion HKD | 2.84% |
| 2018 FY | 1.33 Billion HKD | 3.02% |
| 2018 Q2 | 1.29 Billion HKD | 0.18% |
| 2017 FY | 1.29 Billion HKD | 50.42% |
| 2017 Q4 | 1.29 Billion HKD | 2.95% |
| 2017 Q2 | 1.25 Billion HKD | 46.11% |
| 2016 Q4 | 860.24 Million HKD | 14.28% |
| 2016 FY | 860.24 Million HKD | 23.36% |
| 2016 Q2 | 752.75 Million HKD | 7.95% |
| 2015 FY | 697.33 Million HKD | 65.91% |
| 2015 Q4 | 697.33 Million HKD | 68.37% |
| 2015 Q2 | 414.17 Million HKD | -1.46% |
| 2014 FY | 420.31 Million HKD | 20.74% |
| 2014 Q4 | 420.31 Million HKD | 0.0% |
| 2013 FY | 348.11 Million HKD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 907.46 Million HKD | 6.998% |
| Grand Pharmaceutical Group Limited | 22.51 Billion HKD | 96.252% |
| Extrawell Pharmaceutical Holdings Limited | 1.28 Billion HKD | 34.434% |
| Wai Yuen Tong Medicine Holdings Limited | 2.09 Billion HKD | 59.717% |
| Qianhai Health Holdings Limited | 478.11 Million HKD | -76.518% |
| Lee's Pharmaceutical Holdings Limited | 2.89 Billion HKD | 70.804% |
| Essex Bio-Technology Limited | 2.82 Billion HKD | 70.152% |
| Tongfang Kontafarma Holdings Limited | 1.72 Billion HKD | 51.141% |
| SSY Group Limited | 11.96 Billion HKD | 92.947% |
| JBM (Healthcare) Limited | 1.38 Billion HKD | 39.226% |
| Jacobson Pharma Corporation Limited | 3.48 Billion HKD | 75.796% |
| China Resources Pharmaceutical Group Limited | 271.69 Billion HKD | 99.689% |